PWM
TGTX icon

Parkworth Wealth Management’s TG Therapeutics TGTX Stock Holding History

Parkworth Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$252 Buy
+7
New +$261 ﹤0.01% 873
2025
Q1 		– Sell
-3
Closed -$90 – 1291
2024
Q4 		$90 Buy
+3
New +$86 ﹤0.01% 1015

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkworth Wealth Management's TGTX Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in TG Therapeutics (TGTX) in Q2 2025: 7 shares worth $252. The stake represents ﹤0.01% of the portfolio and ranks #873 among its holdings. This is a return to the name: Parkworth Wealth Management previously reported a position in TGTX as recently as Q4 2024.

Parkworth Wealth Management first reported a position in TGTX in Q4 2024 and has held it in 2 quarters since. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Parkworth Wealth Management held 7 shares of TG Therapeutics worth $252 as of Q2 2025.
  • TG Therapeutics was a new Parkworth Wealth Management position in Q2 2025.
  • TG Therapeutics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #873 holding.
  • Parkworth Wealth Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.